scholarly article | Q13442814 |
P356 | DOI | 10.1200/JCO.2013.50.9984 |
P698 | PubMed publication ID | 24101045 |
P50 | author | Edith A. Perez | Q18389345 |
Mitch Dowsett | Q53099690 | ||
Giuseppe Viale | Q80639743 | ||
Gail H. Vance | Q84512726 | ||
P2093 | author name string | Wedad Hanna | |
Daniel F Hayes | |||
Kimberly H Allison | |||
Patricia A Spears | |||
M Elizabeth H Hammond | |||
David G Hicks | |||
Michael F Press | |||
Robert B Jenkins | |||
Antonio C Wolff | |||
Donald C Allred | |||
John M S Bartlett | |||
Lisa M McShane | |||
Michael Bilous | |||
Pamela B Mangu | |||
Patrick Fitzgibbons | |||
Soonmyung Paik | |||
Antonio C. Wolff | |||
Daniel F. Hayes | |||
David G. Hicks | |||
Donald C. Allred | |||
John M.S. Bartlett | |||
Kimberly H. Allison | |||
Lisa M. McShane | |||
M. Elizabeth H. Hammond | |||
Michael F. Press | |||
Pamela B. Mangu | |||
Patricia A. Spears | |||
Robert B. Jenkins | |||
P433 | issue | 31 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | breast cancer | Q128581 |
Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
P304 | page(s) | 3997-4013 | |
P577 | publication date | 2013-11-01 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | |
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update | |||
P478 | volume | 31 |
Q39292642 | 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study |
Q38821174 | (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer |
Q30315970 | 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts |
Q39272681 | 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer |
Q52600754 | 3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis. |
Q92614334 | 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial |
Q55000437 | 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. |
Q56516407 | 68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study |
Q50223041 | 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. |
Q90602596 | 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up |
Q37414060 | A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis |
Q36206190 | A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation |
Q55322794 | A New Paradigm for Tissue Diagnostics: Tools and Techniques to Standardize Tissue Collection, Transport, and Fixation. |
Q54968815 | A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer. |
Q47577143 | A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors |
Q58423595 | A Practical Approach to the Use of Immunohistochemistry in the Diagnosis and Management of Breast Disease |
Q92140376 | A Rare Case of Triple Positive Metachronous Breast Cancer |
Q38641520 | A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer |
Q61448675 | A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 breast cancer |
Q36860111 | A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression |
Q52680181 | A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. |
Q90589232 | A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell |
Q33639763 | A critical analysis of cancer biobank practices in relation to biospecimen quality |
Q36277170 | A cut-off of 2150 cytokeratin 19 mRNA copy number in sentinel lymph node may be a powerful predictor of non-sentinel lymph node status in breast cancer patients |
Q90352722 | A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+ breast cancers: a 2538-case multicenter study on consecutive surgical specimens |
Q35906737 | A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B. |
Q47107430 | A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity |
Q35863010 | A formalin-free method for stabilizing cells for nucleic acid amplification, hybridization and next-generation sequencing |
Q64264734 | A model for the impact of FFPE section thickness on gene copy number measurement by FISH |
Q40978920 | A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer |
Q104471916 | A negative binomial regression model for risk estimation of 0-2 axillary lymph node metastases in breast cancer patients |
Q38760747 | A new look at the ALK gene in cancer: copy number gain and amplification |
Q47675278 | A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients |
Q47127531 | A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry |
Q55065689 | A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. |
Q60044022 | A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study |
Q88055520 | A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity |
Q42457595 | A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma |
Q88657584 | A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients |
Q51371303 | A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. |
Q92100542 | A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer |
Q41173029 | A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer |
Q38648408 | A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer |
Q89284730 | A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study |
Q86838793 | A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours |
Q37341891 | A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression |
Q36152629 | A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer |
Q51697298 | A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. |
Q92741938 | A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer |
Q93060699 | A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study) |
Q41662372 | A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer |
Q38929949 | A review of consent practices and perspectives for pharmacogenetic testing |
Q96431012 | A self-sustaining endocytic-based loop promotes breast cancer plasticity leading to aggressiveness and pro-metastatic behavior |
Q50990265 | A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. |
Q47146801 | A tissue microRNA signature that predicts the prognosis of breast cancer in young women |
Q37085887 | ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer |
Q34042627 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014. |
Q92257886 | APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer |
Q38374808 | ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis |
Q49721138 | Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers |
Q92639181 | Accelerated Tissue Processing With Minimal Formalin Fixation Time for 9-Gauge Vacuum-Assisted Breast Biopsy Specimens |
Q54311896 | Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations. |
Q36614803 | Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype |
Q34231928 | Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry |
Q96305440 | Actionable gene alterations in an Asian population with triple-negative breast cancer |
Q33608593 | Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes |
Q47813594 | Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer |
Q52675952 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. |
Q52691510 | Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. |
Q38842844 | Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells. |
Q47313470 | Adiposity, Inflammation and Breast Cancer Pathogenesis in Asian Women. |
Q38743961 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer |
Q91738536 | Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis |
Q39018742 | Adjuvant trastuzumab: a 10-year overview of its benefit. |
Q90024930 | Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q |
Q55105639 | Advances in the systemic treatment of triple-negative breast cancer. |
Q38612634 | Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens |
Q38980293 | Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers |
Q39863683 | Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations |
Q90307333 | Affibody Molecules as Targeting Vectors for PET Imaging |
Q50609680 | Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer. |
Q36546821 | Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration |
Q35538100 | Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. |
Q37392829 | Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer |
Q41564734 | Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer |
Q38654175 | Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast |
Q37606324 | Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer |
Q53067561 | An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes. |
Q39037175 | An international study to increase concordance in Ki67 scoring |
Q40417660 | An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors |
Q40466552 | An optimized image analysis algorithm for detecting nuclear signals in digital whole slides for histopathology. |
Q90608713 | Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response |
Q92860600 | Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival |
Q64238242 | Analysis of Hormone Receptor Status in Primary and Recurrent Breast Cancer Via Data Mining Pathology Reports |
Q38677201 | Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer |
Q92085817 | Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study |
Q39369156 | Analytic inquiry: Validation and practical considerations. |
Q41498719 | Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. |
Q38552128 | Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. |
Q55709334 | Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? |
Q37542959 | Androgen Receptor Expression in Breast Carcinoma of Egyptian Patients |
Q57298998 | Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations |
Q48201952 | Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy |
Q92331171 | Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer |
Q40828085 | Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer |
Q42366191 | Androgen receptor expression on circulating tumor cells in metastatic breast cancer. |
Q54328011 | Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. |
Q52627339 | Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? |
Q35088745 | Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options |
Q41092731 | Androgen receptor status predicts development of brain metastases in ovarian cancers. |
Q35631966 | Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays |
Q51310879 | Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. |
Q36021686 | Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype |
Q43276367 | Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast. |
Q36834535 | Application of multispectral imaging in quantitative immunohistochemistry study of breast cancer: a comparative study |
Q55032245 | Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. |
Q91637171 | Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different? |
Q37220987 | Are acinic cell carcinomas of the breast and salivary glands distinct diseases? |
Q36307517 | Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. |
Q64895271 | Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. |
Q39263199 | Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany |
Q34511787 | Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer |
Q91845207 | Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines |
Q90303216 | Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines |
Q47700657 | Assessment of HER-2 status in invasive breast cancer in Brazil. |
Q35841024 | Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method |
Q54256014 | Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. |
Q34446385 | Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer |
Q36194523 | Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China |
Q64114958 | Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry |
Q38384113 | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study |
Q41729795 | Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines |
Q88622458 | Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease |
Q38779230 | Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer |
Q55365832 | Association between Changes in Serum 25-Hydroxyvitamin D Levels and Survival in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy. |
Q45071124 | Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay |
Q55025169 | Association of APEX1 and OGG1 gene polymorphisms with breast cancer risk among Han women in the Gansu Province of China. |
Q42492427 | Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs. |
Q99583844 | Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy |
Q38400780 | Association of preoperative breast MRI features with locoregional recurrence after breast conservation therapy |
Q35944405 | Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study |
Q91570513 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial |
Q38656185 | Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue |
Q36304131 | Automated fluorescent miscroscopic image analysis of PTBP1 expression in glioma |
Q54344831 | Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas. |
Q90643971 | Axillary Pathologic Complete Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer Patients: A Predictive Model Integrating the Imaging Characteristics of Ultrasound Restaging with Known Clinicopathologic Characteristics |
Q33728272 | BI-RADS 3-5 microcalcifications: prediction of lymph node metastasis of breast cancer |
Q47769924 | BRCA mutations in women with inflammatory breast cancer |
Q50108671 | BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. |
Q36224769 | BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer |
Q53627332 | Bcl2 and Ki67 refine prognostication in luminal breast cancers. |
Q36859845 | Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection. |
Q53509601 | Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer. |
Q38933076 | Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors |
Q26781177 | Biological markers of invasive breast cancer |
Q38893074 | Biology and Management of Patients With Triple-Negative Breast Cancer |
Q38696790 | Biomarker assessment and molecular testing for prognostication in breast cancer |
Q41708696 | Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. |
Q26863672 | Biomarker validation and testing |
Q48353102 | Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology |
Q38150774 | Biomarkers of drugs targeting HER-family signalling in cancer. |
Q92011636 | Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update |
Q52911366 | Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. |
Q58608725 | Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features |
Q90655998 | Brain metastasis-related microRNAs in patients with advanced breast cancer |
Q33666339 | Breast Biomarkers-Comparison on Whole Section and Tissue Microarray Section |
Q35758871 | Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells |
Q92916959 | Breast Cancer Heterogeneity in Primary and Metastatic Disease |
Q97423486 | Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event |
Q38812876 | Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results |
Q35674339 | Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer |
Q64892768 | Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. |
Q42004516 | Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach? |
Q58703254 | Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients |
Q57112840 | Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis |
Q41545885 | Breast cancer in Angola, molecular subtypes: a first glance |
Q48102254 | Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture. |
Q40076929 | Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis |
Q38386346 | Breast cancer under age 40: a different approach |
Q54466502 | Breast cancer: updated guideline recommendations for HER2 testing. |
Q42377436 | Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification |
Q38887777 | Breast fine needle aspiration continues to be relevant in a large academic medical center: experience from Massachusetts General Hospital |
Q38255904 | Breast pathology second review identifies clinically significant discrepancies in over 10% of patients |
Q37371183 | Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections |
Q33840191 | Budget impact analysis of a breast rapid diagnostic unit |
Q49498310 | Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers |
Q38365298 | CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer |
Q34590820 | CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast |
Q37094941 | CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ. |
Q64284492 | CD9 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Lobular Carcinoma |
Q42317491 | CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers |
Q39358281 | CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial |
Q33728102 | CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient |
Q89172410 | CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer |
Q38974995 | Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease? |
Q36605624 | Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary |
Q35879887 | Cancer biomarker discovery and validation |
Q42472874 | Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. |
Q58556410 | Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma |
Q36544839 | Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas |
Q64899508 | Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. |
Q61806002 | Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer |
Q34371646 | Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology |
Q38750783 | Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. |
Q59795879 | Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy |
Q33688726 | Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study |
Q91559381 | Centromere 17 copy number gain reflects chromosomal instability in breast cancer |
Q47164059 | Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? |
Q40188581 | Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy. |
Q90619966 | Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value |
Q33739585 | Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer |
Q48093728 | Changes in c-erbB-2 Immunoexpression in Feline Endometrial Adenocarcinomas. |
Q37385681 | Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade |
Q40832706 | Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients |
Q37588488 | Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer |
Q90567499 | Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases |
Q50893707 | Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization. |
Q52595390 | Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. |
Q92551228 | Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts |
Q43923959 | Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania |
Q47593035 | Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. |
Q64934986 | Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. |
Q64996424 | Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. |
Q33697429 | Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women |
Q57461650 | Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study |
Q55647210 | Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. |
Q92579947 | Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma |
Q36193912 | Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. |
Q35945945 | Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer |
Q40847702 | Circulating Tumor Cells. |
Q37684125 | Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer |
Q34042565 | Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression. |
Q36237815 | Claudin-Low Breast Cancer; Clinical & Pathological Characteristics |
Q41443052 | Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint |
Q42335970 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines |
Q57517727 | Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative |
Q47196323 | Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients |
Q41662380 | Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy |
Q64940482 | Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting. |
Q90484961 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond |
Q64236586 | Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer |
Q48409259 | Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients |
Q26800996 | Clinical implications of the intrinsic molecular subtypes of breast cancer |
Q40977689 | Clinical outcome of brain metastases differs significantly among breast cancer subtypes |
Q90149717 | Clinical outcomes of an intraoperative surgical margin assessment using the fresh frozen section method in patients with invasive breast cancer undergoing breast-conserving surgery - a single center analysis |
Q64096309 | Clinical potential of mass spectrometry-based proteogenomics |
Q36974534 | Clinical predictors of long-term survival in HER2-positive metastatic breast cancer |
Q41701909 | Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer |
Q47260496 | Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years |
Q40811309 | Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival |
Q40135743 | Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients. |
Q87629019 | Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers |
Q38754717 | Clinical utility of gene-expression signatures in early stage breast cancer |
Q64237850 | Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer |
Q36473017 | Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer |
Q41956083 | Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence |
Q91755986 | Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial |
Q64272441 | Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma |
Q92618058 | Clinicopathologic characteristics of HER2-positive pure mucinous breast carcinoma: a systematic investigation into an unusual tumor |
Q92389536 | Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample |
Q35675665 | Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center |
Q41198035 | Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer |
Q50655660 | Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. |
Q36820188 | Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ |
Q36914879 | Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast |
Q40343596 | Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. |
Q104486591 | Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer |
Q34483478 | Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients |
Q42386629 | Coamplification with colocalization of the human epidermal growth factor receptor 2 and centromeric-17 signals on fluorescence in situ hybridization in invasive breast carcinoma: An exceedingly rare finding |
Q39036665 | Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas |
Q99608951 | Combination of preoperative fibrinogen concentration and neutrophil-to-lymphocyte ratio for prediction of the prognosis of patients with resectable breast cancer |
Q49409380 | Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study |
Q92237440 | Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer |
Q93361007 | Combining fluorescence-based image segmentation and automated microfluidics for ultrafast cell-by-cell assessment of biomarkers for HER2-type breast carcinoma |
Q48265826 | Combining multiparametric MRI with receptor information to optimize prediction of pathologic response to neoadjuvant therapy in breast cancer: preliminary results. |
Q50301520 | Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer. |
Q55425539 | Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. |
Q38648453 | Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer |
Q89171762 | Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma |
Q35750049 | Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases |
Q41997321 | Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry |
Q51560507 | Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer: A Cohort Study Emphasizing Equivocal Cases. |
Q54348234 | Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. |
Q38681307 | Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period |
Q64914379 | Comparison of Molecular Subtypes of Carcinoma of the Breast in Two Different Age Groups: A Single Institution Experience. |
Q47788774 | Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results |
Q55171730 | Comparison of Pathological Prognostic Stage and Anatomic Stage Groups According to the Updated Version of the American Joint Committee on Cancer (AJCC) Breast Cancer Staging 8th Edition. |
Q58767252 | Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform |
Q45814350 | Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program. |
Q33574310 | Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer |
Q37438701 | Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma |
Q61817310 | Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples |
Q37246183 | Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection |
Q64254353 | Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 |
Q55126874 | Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. |
Q37719989 | Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma |
Q53293967 | Complexity in regulation of microRNA machinery components in invasive breast carcinoma. |
Q64081080 | Complicated prognostic values of CCL28 in breast cancer by subtype |
Q40064664 | Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score |
Q48105836 | Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. |
Q41571663 | Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. |
Q36356185 | Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. |
Q38830663 | Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. |
Q40264759 | Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy |
Q34084063 | Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification |
Q42282776 | Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients |
Q92837814 | Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China |
Q51707520 | Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. |
Q92501000 | Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial |
Q37582617 | Conditional disease-free survival among patients with breast cancer |
Q35981197 | Conference report from the 2015 OECI Oncology Days, Portugal, 22-24 June-tumour heterogeneity and next generation sequencing: morphology and technology |
Q26747282 | Confronting the Care Delivery Challenges Arising from Precision Medicine |
Q98291200 | Conserving the lymphatics from the arm using fluorescence imaging in patients with breast cancer at high risk of postoperative lymphedema: a pilot study |
Q36559818 | Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer |
Q42113818 | Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes |
Q47763856 | Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer |
Q54940119 | Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. |
Q38830273 | Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. |
Q48270057 | Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. |
Q36115834 | Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods |
Q48087902 | Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion. |
Q54337373 | Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer. |
Q34371749 | Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas |
Q53825199 | Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience. |
Q48175913 | Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013. |
Q37607412 | Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients. |
Q36368001 | Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators? |
Q54324778 | Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy. |
Q36116276 | Cost-utility analyses of drug therapies in breast cancer: a systematic review. |
Q48155048 | Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough? |
Q35574950 | Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues |
Q54311366 | Cystic apocrine ductal carcinoma in situ with increased EGFR expression, trisomy 7, and associated focal invasion. |
Q53423659 | Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity. |
Q55409038 | Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population. |
Q53277939 | Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma. |
Q37057171 | Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer |
Q55027564 | Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer. |
Q61812190 | DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway |
Q48177736 | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. |
Q41705524 | Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate |
Q59128695 | Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes |
Q91693727 | De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study |
Q39421814 | De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance |
Q47727855 | Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer |
Q35586697 | Defining breast cancer intrinsic subtypes by quantitative receptor expression |
Q47096644 | Demographic Characteristics, Survival and Prognostic Factors of Early Breast Cancer Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cohort Study |
Q47846945 | Detection and genomic characterization of a mammary-like adenocarcinoma. |
Q90280131 | Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform |
Q37309906 | Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT |
Q100503891 | Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing |
Q92381716 | Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma |
Q97905188 | Developing a routine lab test for absolute quantification of HER2 in FFPE breast cancer tissues using Quantitative Dot Blot (QDB) method |
Q43019940 | Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT. |
Q38611899 | Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience. |
Q38383094 | Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer |
Q35752868 | Development and verification of the PAM50-based Prosigna breast cancer gene signature assay |
Q26774670 | Development of Companion Diagnostics |
Q65558792 | Development of Electrochemical Immunosensors towards Point-of-care Cancer Diagnostics: Clinically Relevant Studies |
Q36182596 | Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. |
Q37000037 | Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements |
Q90664744 | Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study |
Q93164688 | Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer |
Q89514068 | Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer |
Q58554058 | Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer |
Q35043734 | Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging |
Q38390425 | Developments in biospecimen research |
Q37266321 | Diagnostic Pitfalls in Papillary Lesions of the Breast: Experience from a Single Tertiary Care Center |
Q36502246 | Dietary effects of mead acid on N-methyl-N-nitrosourea-induced mammary cancers in female Sprague-Dawley rats |
Q35813033 | Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013 |
Q37559408 | Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women |
Q36689113 | Differentiation between genetic mutations of breast cancer by breath volatolomics. |
Q36544438 | Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples |
Q94340372 | Digital and Computational Pathology: Bring the Future into Focus |
Q45943609 | Digital image analysis in breast pathology-from image processing techniques to artificial intelligence. |
Q40107322 | Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens |
Q39967968 | Digital image analysis outperforms manual biomarker assessment in breast cancer. |
Q89684109 | Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence |
Q38168792 | Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. |
Q38377039 | Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample |
Q41281294 | Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site |
Q55066506 | Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. |
Q36610188 | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be t |
Q38629753 | Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China |
Q33685227 | Distant recurrence risk following early ipsilateral breast tumor recurrence |
Q58701459 | Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center |
Q60302395 | Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer |
Q40257398 | Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer. |
Q93036043 | Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas |
Q41472829 | Does the 1H-NMR plasma metabolome reflect the host-tumor interactions in human breast cancer? |
Q90093747 | Downregulation of N-myc and STAT Interactor Protein Predicts Aggressive Tumor Behavior and Poor Prognosis in Invasive Ductal Carcinoma |
Q57039390 | Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues |
Q38815180 | Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples |
Q91741236 | Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer |
Q90568473 | Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients |
Q99418051 | Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells |
Q38696796 | Ductal carcinoma in situ - update on risk assessment and management |
Q92377712 | Ductal carcinoma in situ of the breast: immune cell composition according to subtype |
Q37490083 | Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression |
Q47107525 | EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer |
Q90297672 | ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling |
Q49568845 | ERBB2 mutation: A promising target in non-squamous cervical cancer. |
Q53645637 | Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival. |
Q47161842 | Eco-Friendly Formulated Zinc Oxide Nanoparticles: Induction of Cell Cycle Arrest and Apoptosis in the MCF-7 Cancer Cell Line |
Q35098320 | Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. |
Q37597853 | Effective implementation of novel MET pharmacodynamic assays in translational studies |
Q38375607 | Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer |
Q54216352 | Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. |
Q50595872 | Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results. |
Q39683758 | Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. |
Q44834419 | Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients |
Q54957080 | Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. |
Q38624619 | Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients |
Q90652072 | Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers |
Q53059106 | Endobronchial Pagetoid Spread of a Breast Carcinoma Metastatic to the Lung. |
Q55113713 | Ensemble outlier detection and gene selection in triple-negative breast cancer data. |
Q92922203 | Epidermal Growth Factor and Adenosine Triphosphate Induce Natrium Iodide Symporter Expression in Breast Cancer Cell Lines |
Q28084216 | Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer |
Q58608173 | Epigenetic profiling for the molecular classification of metastatic brain tumors |
Q34011318 | Epigenomic alterations in breast carcinoma from primary tumor to locoregional recurrences. |
Q59339939 | Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology |
Q36145725 | Epithelial-Mesenchymal Transition Phenotype Is Associated with Clinicopathological Factors That Indicate Aggressive Biological Behavior and Poor Clinical Outcomes in Invasive Breast Cancer. |
Q47137308 | Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study |
Q91633172 | Establishment of Simple Nomograms for Predicting Axillary Lymph Node Involvement in Early Breast Cancer |
Q64086596 | Establishment of primary human breast cancer cell lines using "pulsed hypoxia" method and development of metastatic tumor model in immunodeficient mice |
Q88752161 | Estrogen receptor (ESR1) mutation in bone metastases from breast cancer |
Q38842674 | Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review |
Q89886956 | Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-anal |
Q36595121 | Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers |
Q93377567 | Evaluation of Estrogen and Progesterone Receptors and Her-2 Expression with Grading in the Fine-needle Aspirates of Patients with Breast Carcinoma |
Q37367705 | Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer |
Q47377842 | Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy |
Q37607969 | Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period |
Q49594093 | Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer |
Q50016491 | Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer |
Q88680520 | Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study |
Q90282144 | Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A |
Q40180964 | Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique |
Q93384504 | Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas |
Q88391705 | Expanding definitions of HER2 positivity |
Q37629540 | Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer |
Q41205623 | Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis |
Q90537994 | Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy |
Q89128693 | Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression |
Q92286634 | Expression of Podoplanin in Mammary Cancers in Female Dogs |
Q35583904 | Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics |
Q38423284 | Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer |
Q37547952 | Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer |
Q47149324 | Expression of and correlation between BCL6 and ZEB family members in patients with breast cancer |
Q51609262 | Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. |
Q52938712 | Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer. |
Q36292201 | Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions |
Q58083308 | Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion |
Q36342637 | Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma |
Q36014223 | Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status |
Q48141048 | Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome |
Q37075615 | Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study |
Q57105820 | F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men |
Q51168093 | FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. |
Q51503743 | FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool. |
Q48550447 | FISH in triple-negative breast cancer: a possible strategy for the future? |
Q37406841 | FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics. |
Q51062308 | FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells. |
Q55517966 | FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients. |
Q48348098 | Factors predictive of occult nipple-areolar complex involvement in patients with carcinoma in situ of the breast. |
Q35803396 | Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer |
Q37148958 | Fascin-1 as a novel diagnostic marker of triple-negative breast cancer |
Q90717131 | Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer |
Q38399858 | Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients. |
Q92083474 | Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers |
Q35743009 | Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer |
Q50955504 | Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast. |
Q36546414 | First description of a sporadic breast cancer in a woman with BRCA1 germline mutation |
Q34104204 | First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer |
Q47965803 | First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer |
Q100758028 | Fluorescence in situ hybridisation analysis of human epidermal growth factor receptor 2 status for breast cancer cases in Brunei Darussalam |
Q53364971 | Fluorescence in situ hybridization (FISH) results in HER2 score 1+ and 2+ breast cancers. |
Q89668743 | Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients |
Q35083252 | For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. |
Q55155438 | Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice. |
Q40324533 | Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry |
Q87232807 | Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort |
Q42491917 | Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. |
Q57793316 | Frequent ESR1 and CDK Pathway Copy Number Alterations in Metastatic Breast Cancer |
Q54284515 | Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. |
Q28084982 | From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? |
Q35284728 | Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study |
Q53362356 | Fut3 role in breast invasive ductal carcinoma: Investigating its gene promoter and protein expression. |
Q50013621 | GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer |
Q51502502 | GATA3 expression in primary vulvar Paget disease: a potential pitfall leading to misdiagnosis of pagetoid urothelial intraepithelial neoplasia. |
Q33761830 | GD2 expression in breast cancer. |
Q41714879 | Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method |
Q34458036 | Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method |
Q37447938 | Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines |
Q40269605 | Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases |
Q37377544 | Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma |
Q36844915 | Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology |
Q47882632 | Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma |
Q40505249 | Genetic code expansion for multiprotein complex engineering. |
Q37372455 | Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer |
Q55394663 | Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. |
Q37706844 | Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray |
Q38407595 | Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup |
Q51521953 | Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. |
Q42495798 | Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures |
Q60908056 | Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer |
Q90393213 | Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab |
Q58801101 | Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications |
Q46225087 | Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. |
Q36366309 | Genomic landscape of adenoid cystic carcinoma of the breast |
Q42498238 | Genomic profiling of breast cancer in African-American women using MammaPrint. |
Q42510239 | Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. |
Q92589578 | Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity |
Q92610423 | Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations |
Q92627804 | Genomics applied to the treatment of breast cancer |
Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
Q36847816 | Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories |
Q54579368 | Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. |
Q34202981 | GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images |
Q37687943 | Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry |
Q36695807 | Guidelines for cytogenetic investigations in tumours |
Q36762236 | HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens |
Q50115014 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers. |
Q36094918 | HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland. |
Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
Q92839110 | HER-2 status and its clinicopathologic significance in breast cancer in patients from southwest China: re-evaluation of correlation between results from FISH and IHC |
Q91997875 | HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters |
Q34506951 | HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas |
Q64063349 | HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer |
Q39983856 | HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline |
Q48147789 | HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category |
Q39442160 | HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials |
Q51175484 | HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer. |
Q50125137 | HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility. |
Q33686182 | HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer |
Q36724623 | HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder |
Q33925610 | HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patients |
Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
Q46188099 | HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics |
Q38914809 | HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations. |
Q27026178 | HER2 as a therapeutic target in head and neck squamous cell carcinoma |
Q90208904 | HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma |
Q92465974 | HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor |
Q47097049 | HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients. |
Q90626593 | HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population |
Q47370686 | HER2 expression patterns in paired primary and metastatic endometrial cancer lesions |
Q38364900 | HER2 expression status in diverse cancers: review of results from 37,992 patients |
Q35929360 | HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide |
Q40714642 | HER2 gene copy number and breast cancer-specific survival |
Q26741253 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice |
Q92685589 | HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer |
Q48330458 | HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features |
Q35211263 | HER2 in solid tumors: more than 10 years under the microscope; where are we now? |
Q37075632 | HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
Q47965547 | HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. |
Q51541370 | HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. |
Q40419939 | HER2 mRNA transcript quantitation in breast cancer |
Q61446731 | HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women |
Q36151207 | HER2 status determination: analyzing the problems to find the solutions |
Q36014239 | HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features. |
Q90593024 | HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features |
Q38326102 | HER2 testing and its predictive utility in anti-HER2 breast cancer therapy |
Q39174711 | HER2 testing in gastric cancer: results of a German expert meeting |
Q92577910 | HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study |
Q37588232 | HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status |
Q92004464 | HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer |
Q35551522 | HER2-directed therapy: current treatment options for HER2-positive breast cancer |
Q34499609 | HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development |
Q39034850 | HER2-positive breast cancer |
Q38648765 | HER2-positive breast cancer is lost in translation: time for patient-centered research |
Q40391145 | HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable |
Q39040859 | HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? |
Q33741544 | HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study |
Q34499615 | HER2/neu testing in primary colorectal carcinoma |
Q35748129 | HER2/neu-directed therapy for biliary tract cancer |
Q36040463 | HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer |
Q40649343 | HMGA1 overexpression is associated with a particular subset of human breast carcinomas |
Q33823200 | HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells |
Q37644205 | Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy |
Q33623561 | Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases. |
Q44347751 | Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization |
Q54356587 | Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain. |
Q33767081 | Heterogeneity of Diffusion-Weighted Imaging in Tumours and the Surrounding Stroma for Prediction of Ki-67 Proliferation Status in Breast Cancer |
Q57058202 | High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients |
Q55345031 | High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. |
Q37142882 | High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. |
Q57124774 | High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer |
Q41297799 | High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer |
Q47561567 | High expression of PU.1 is associated with Her-2 and shorter survival in patients with breast cancer |
Q53192082 | High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. |
Q37074050 | High prevalence of luminal B breast cancer intrinsic subtype in Colombian women |
Q35203546 | High tumor budding stratifies breast cancer with metastatic properties |
Q37682595 | High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial |
Q91117914 | High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer |
Q64264397 | Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era |
Q38944865 | Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. |
Q53130487 | Higher expression of EpCAM is associated with poor clinical and pathological responses in breast cancer patients undergoing neoadjuvant chemotherapy. |
Q64113608 | Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics |
Q53512628 | Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. |
Q49061414 | Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. |
Q92716347 | Homologous recombination DNA repair defects in PALB2-associated breast cancers |
Q64094297 | Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management |
Q92293794 | Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies |
Q92064459 | Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands |
Q99237864 | Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors |
Q90781848 | Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel |
Q34223494 | Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications |
Q48219599 | Human Metaplastic Breast Carcinoma and Decorin |
Q64039988 | Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease |
Q35038694 | Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features |
Q39661792 | Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study |
Q38626665 | Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing? |
Q36450387 | Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting. |
Q37200784 | Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology |
Q36392789 | Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy? |
Q37013995 | Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma |
Q49412994 | Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms |
Q48336597 | Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration. |
Q55381932 | Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. |
Q42003695 | Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis |
Q61447409 | Image Analysis of HER2 Immunohistochemical Staining of Surgical Breast Cancer Specimens |
Q40217601 | Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma |
Q38401251 | Imaging Surveillance for Survivors of Breast Cancer: Correlation between Cancer Characteristics and Method of Detection |
Q35870134 | Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery |
Q91776798 | Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients |
Q52956295 | Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable. |
Q64999098 | Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray. |
Q64235723 | Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas |
Q41809618 | Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas |
Q33741582 | Immunohistochemical Study of MUC1, MUC2 and MUC5AC Expression in Primary Breast Carcinoma |
Q35159751 | Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy. |
Q51777015 | Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma. |
Q57107439 | Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing |
Q48070124 | Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test |
Q92281250 | Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma |
Q35759456 | Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests. |
Q51728141 | Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer. |
Q34029360 | Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas |
Q40987749 | Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis |
Q55364226 | Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification. |
Q92830547 | Immunohistochemistry-Enabled Precision Medicine |
Q49646394 | Immunophenotypic profile of tumor buds in breast cancer. |
Q47716532 | Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory |
Q92451331 | Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study |
Q57470007 | Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer |
Q89357387 | Impact of Micrometastatic Axillary Nodes on Survival of Breast Cancer Patients with Tumors ≤2 cm |
Q35810073 | Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience |
Q40979375 | Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients |
Q40338226 | Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer |
Q92354821 | Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients |
Q44541840 | Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research |
Q50075112 | Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. |
Q64998946 | Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). |
Q99630222 | Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database |
Q30369607 | Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation |
Q48142637 | Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines |
Q53095268 | Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study. |
Q91272391 | Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results |
Q30996906 | Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data |
Q64961265 | Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. |
Q92691435 | Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort |
Q45851017 | Implementing personalized cancer care |
Q50056206 | Improving accuracy of breast cancer biomarker testing in India. |
Q53118370 | In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. |
Q40919195 | In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading |
Q33812042 | In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients |
Q36109108 | In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer |
Q86842053 | In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival |
Q51367692 | Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. |
Q45134639 | Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System |
Q90700166 | Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice |
Q49466873 | Increased expression of mitochondrial transcription factor A and nuclear respiratory factor-1 predicts a poor clinical outcome of breast cancer |
Q40770256 | Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target. |
Q92990334 | Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging |
Q88205410 | Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer |
Q38777813 | Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer |
Q41012013 | Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). |
Q47291975 | Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer |
Q91526464 | Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling |
Q64957213 | Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer. |
Q92890756 | Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma |
Q91796421 | Interleukin-17 and matrix metalloprotease-9 expression in the mycetoma granuloma |
Q45162655 | Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer. |
Q52974218 | Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors. |
Q54962807 | Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates. |
Q92920230 | Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients |
Q33841547 | Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. |
Q35633666 | Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification |
Q59132342 | Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors |
Q52618828 | Intratumoral Heterogeneity of ERBB2 Amplification and HER2 Expression in Micropapillary Urothelial Carcinoma. |
Q47176267 | Intrinsic Subtypes of Breast Cancers Initially Assessed as Probably Benign or of Low Suspicion on Ultrasonography Differ According to Tumor Size |
Q89572743 | Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay |
Q64115873 | Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association |
Q96171987 | Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas |
Q30416537 | Invasive cribriform carcinoma of the breast: A report of nine cases and a review of the literature |
Q35905268 | Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved |
Q53462538 | Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? |
Q38221886 | Investigational therapies targeting the ErbB family in oesophagogastric cancer |
Q31048851 | Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment |
Q58605259 | Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial) |
Q36973465 | KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors |
Q50045477 | Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. |
Q51015726 | Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value? |
Q37658237 | Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy |
Q37596690 | Ki-67 as a prognostic marker according to breast cancer molecular subtype |
Q91939079 | Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study |
Q52680900 | Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. |
Q37578368 | LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer |
Q47403498 | LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness |
Q47138636 | Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers. |
Q48249374 | Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment. |
Q100961545 | Landscape of clinically actionable mutations in breast cancer 'A cohort study' |
Q38992588 | Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer |
Q48012424 | Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma |
Q33802722 | Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool |
Q38213543 | Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy |
Q92433344 | Life-threatening metastasis was suppressed by trastuzumab containing regimen in a patient with Her2-negative breast cancer |
Q60539186 | Lifetime-engineered NIR-II nanoparticles unlock multiplexed in vivo imaging |
Q55070669 | Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer. |
Q37367411 | Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment |
Q28083233 | Long term side effects of adjuvant chemotherapy in patients with early breast cancer |
Q90418604 | Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement |
Q41142443 | Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report |
Q38413284 | Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer |
Q41547969 | Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. |
Q58550839 | Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV |
Q64101361 | Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology |
Q35611160 | Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. |
Q92876894 | Luminal B is the Most Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia |
Q64905115 | Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. |
Q39286355 | MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas |
Q34116451 | MMP-9 expression varies according to molecular subtypes of breast cancer |
Q89948271 | MRI Radiomic Features: Association with Disease-Free Survival in Patients with Triple-Negative Breast Cancer |
Q47389056 | MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. |
Q47391427 | MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene |
Q42363795 | MYC Immunohistochemistry Predicts MYC Rearrangements by FISH. |
Q36907273 | MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer |
Q92509640 | Machine learning-based prediction of breast cancer growth rate in vivo |
Q64923060 | Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. |
Q38317182 | Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. |
Q35920570 | Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer |
Q51148400 | Male Breast Cancer. |
Q39022639 | Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program |
Q64067550 | Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort |
Q42516409 | Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes |
Q41545259 | MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer. |
Q51252463 | Margins: a status report from the Annual Meeting of the American Society of Breast Surgeons. |
Q36009610 | Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer |
Q36510875 | Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. |
Q26752780 | Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
Q51107564 | Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. |
Q54350939 | Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. |
Q64232817 | Metachronous bilateral triple-negative breast cancer associated with neurofibromatosis type 1: A case report |
Q91361607 | Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy |
Q35911470 | Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. . |
Q91766790 | Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center |
Q37743489 | MiRNA-27a promotes the proliferation and invasion of human gastric cancer MGC803 cells by targeting SFRP1 via Wnt/β-catenin signaling pathway |
Q57106460 | MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers |
Q64089665 | Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes |
Q27316870 | Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis |
Q48194558 | Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer |
Q37130372 | Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations |
Q55177941 | Micromolecular methods for diagnosis and therapeutic strategy: a case study. |
Q53070572 | Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. |
Q64109020 | Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1-2 and cN0 breast cancer |
Q92281997 | Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability |
Q53523972 | Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. |
Q26772870 | Molecular Imaging of Biomarkers in Breast Cancer |
Q28072513 | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
Q64106622 | Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells |
Q50045468 | Molecular Subtypes and Local-Regional Control of Breast Cancer. |
Q42511857 | Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers |
Q49648562 | Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size |
Q26751172 | Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer |
Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
Q33729715 | Molecular Testing of Lung Cancers |
Q42687892 | Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population |
Q26800626 | Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation |
Q92538958 | Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes |
Q91904654 | Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing |
Q64921722 | Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target. |
Q51711213 | Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients. |
Q35965925 | Molecular heterogeneity in adjacent cells in triple-negative breast cancer |
Q38236904 | Molecular markers for breast cancer diagnosis, prognosis and targeted therapy |
Q93000430 | Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens |
Q33731350 | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine |
Q34723641 | Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. |
Q42508624 | Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. |
Q38184381 | Molecular tests as prognostic factors in breast cancer |
Q49545664 | Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact |
Q41821797 | Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification |
Q39014708 | Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets |
Q48104335 | Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer |
Q100525979 | Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma |
Q39467942 | Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with "Polysomy 17". |
Q33688612 | Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study |
Q38758647 | Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections |
Q88258261 | Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases |
Q34764681 | Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications |
Q34654793 | Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences |
Q46107985 | Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. |
Q33450398 | NDER: A novel web application using annotated whole slide images for rapid improvements in human pattern recognition |
Q92617209 | NDRG3 protein expression is associated with aggressive biologic phenotype and unfavorable outcome in patients with invasive breast cancer |
Q42366735 | NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry. |
Q26782856 | NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer |
Q64238212 | Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments |
Q53084708 | Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. |
Q42669105 | Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer. |
Q57108415 | Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer |
Q39375196 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. |
Q38658509 | Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. |
Q99614331 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase |
Q48247756 | Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). |
Q92552262 | Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri |
Q64981225 | Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. |
Q38692311 | Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. |
Q92953592 | Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo |
Q48111187 | New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers. |
Q47105039 | New Agents for the Management of Advanced HER2-Positive Breast Cancer |
Q89612527 | New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified |
Q38782016 | New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer |
Q51232753 | Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. |
Q64080457 | Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management |
Q51195482 | Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. |
Q26801745 | Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection |
Q27324543 | Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing |
Q98467126 | Novel targeted therapies for metastatic breast cancer |
Q33887682 | Novel therapeutic strategies in the treatment of triple-negative breast cancer |
Q59135024 | OCT4, SOX2, and NAN OG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2 + breast cancer patients |
Q38436984 | Obesity and breast cancer: not only a risk factor of the disease |
Q55285404 | Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. |
Q36280470 | Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance |
Q101564262 | Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation |
Q38420347 | Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer |
Q92716047 | Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer |
Q39450470 | Operation with less adjuvant therapy for elderly breast cancer. |
Q54197932 | Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough? |
Q35239634 | Optimal systemic therapy for early breast cancer in women: a clinical practice guideline |
Q35673706 | Optimizing HER2 assessment in breast cancer: application of automated image analysis |
Q33756398 | Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer |
Q35896153 | Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute |
Q38811462 | Organochlorine pesticides accumulation and breast cancer: A hospital-based case-control study |
Q37103673 | Outcome Disparities in African American Compared with European American Women with ER+HER2- Tumors Treated within an Equal-Access Health Care System |
Q64952029 | Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. |
Q40719325 | Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience. |
Q51136930 | Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. |
Q35687851 | Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. |
Q38378337 | Ovarian carcinoma diagnosis: the clinical impact of 15 years of change |
Q34478105 | Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis |
Q37714123 | Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancer |
Q55176796 | Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer. |
Q34675545 | P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer |
Q46990125 | PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations |
Q37704352 | PD-L1 Expression in Lung Cancer |
Q50035044 | PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. |
Q64955321 | PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. |
Q50068205 | PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. |
Q35552005 | PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects |
Q47095045 | PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival. |
Q90645887 | Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel |
Q38252702 | Pathological examination of breast cancer biomarkers: current status in Japan |
Q33873330 | Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy |
Q48148198 | Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification. |
Q92433445 | Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy |
Q37316607 | Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis |
Q35663687 | Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies |
Q26795376 | Personalized Medicine: Genomics Trials in Oncology |
Q47199187 | Personalized cancer therapy: leveraging a knowledge base for clinical decision-making |
Q38848389 | Perspectives of HER2-targeting in gastric and esophageal cancer |
Q33364587 | Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle |
Q49668714 | Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety stu |
Q98906952 | Pervasive chromosomal instability and karyotype order in tumour evolution |
Q38573858 | Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy |
Q48212691 | Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. |
Q93039201 | Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (PREX1) is a Novel Predictor of Prognosis for Breast Cancer Patients: A Retrospective Case Series |
Q57469231 | Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab |
Q33810500 | Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations |
Q55265106 | Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. |
Q47209176 | Physician interpretation of genomic test results and treatment selection. |
Q36432099 | Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) |
Q34134105 | Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas |
Q38726641 | Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review |
Q35647723 | Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases |
Q47161220 | Pleomorphic lobular carcinoma: is it more similar to a classic lobular cancer or to a high-grade ductal cancer? |
Q94474399 | Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy |
Q57071024 | Polymorphisms in and are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy |
Q64095962 | Polymorphisms in are associated with age and differentiation of triple-negative breast cancer patients |
Q36640368 | Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility. |
Q57025247 | Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype |
Q38833288 | Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression |
Q90315028 | Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022 |
Q88598954 | Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial |
Q42316809 | Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis |
Q50197859 | Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: a 12-year prospective clinical study. |
Q38551394 | Precision medicine for metastatic breast cancer--limitations and solutions. |
Q36963554 | Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. |
Q90677931 | Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles |
Q49912739 | Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients |
Q94526113 | Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer |
Q61802758 | Prediction of high nodal burden with ultrasound and magnetic resonance imaging in clinically node-negative breast cancer patients |
Q58101133 | Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer |
Q55362114 | Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. |
Q98386288 | Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy |
Q40852747 | Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer |
Q39170872 | Predictive biomarkers along gastric cancer pathogenetic pathways |
Q38687963 | Predictive factors on outcomes in metaplastic breast cancer. |
Q38257364 | Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues |
Q55066764 | Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. |
Q64998084 | Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. |
Q59330044 | Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer |
Q37056933 | Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery |
Q37492154 | Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study |
Q37130345 | Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 |
Q38859150 | Preoperative MRI features associated with lymphovascular invasion in node-negative invasive breast cancer: A propensity-matched analysis. |
Q90610229 | Preoperative axillary nodal staging with ultrasound and magnetic resonance imaging: predictive values of quantitative and semantic features |
Q34967515 | Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer |
Q57300518 | Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib |
Q33651817 | Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study |
Q89537639 | Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer |
Q43526241 | Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States |
Q30316383 | Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). |
Q55279483 | Primary ductal adenocarcinoma of lacrimal gland: Two case reports and review of the literature. |
Q34121611 | Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. |
Q27012540 | Profile of neratinib and its potential in the treatment of breast cancer |
Q39166261 | Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01). |
Q33646271 | Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers |
Q38687389 | Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients |
Q37735963 | Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer |
Q37176151 | Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer |
Q53702177 | Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer |
Q36299320 | Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer |
Q94593638 | Prognostic Significance of the Tumor-Stromal Ratio in Invasive Breast Cancer and a Proposal of a New Ts-TNM Staging System |
Q64917707 | Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer |
Q89465480 | Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab |
Q35593081 | Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly |
Q89644502 | Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis |
Q47734351 | Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. |
Q38778532 | Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer |
Q50457473 | Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. |
Q101403266 | Prognostic and predictive parameters in breast pathology: a pathologist's primer |
Q37327661 | Prognostic and predictive value of Ki-67 in triple-negative breast cancer |
Q92819254 | Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response |
Q36180689 | Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer |
Q34582515 | Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer. |
Q38749528 | Prognostic impact of HER-2 Subclonal Amplification in breast cancer |
Q35148813 | Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers. |
Q52880311 | Prognostic implications of securin expression and sub-cellular localization in human breast cancer. |
Q34996098 | Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients |
Q93072009 | Prognostic markers in salivary gland cancer and their impact on survival |
Q37175089 | Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies |
Q36600002 | Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis |
Q42464923 | Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. |
Q48261136 | Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma. |
Q57298068 | Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer |
Q44217841 | Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers |
Q37671450 | Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients |
Q61798870 | Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer |
Q36107543 | Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques |
Q89677965 | Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer |
Q26798078 | Progress in adjuvant chemotherapy for breast cancer: an overview |
Q52589023 | Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. |
Q51017227 | Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer. |
Q88468281 | Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas |
Q93270250 | Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients |
Q29011698 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer |
Q38748131 | Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications. |
Q35816286 | Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach |
Q58416668 | Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work |
Q38596988 | Quality assurance in clinical trials--the role of pathology |
Q36134039 | Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues. |
Q64112956 | Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes |
Q53581875 | Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes. |
Q93089134 | Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer |
Q41601026 | Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging |
Q38633233 | Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness. |
Q35343184 | Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival |
Q35251561 | Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic |
Q36261449 | Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples |
Q35347732 | Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer |
Q48142619 | Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. |
Q38370716 | Radiation therapy in the locoregional treatment of triple-negative breast cancer |
Q54116157 | Radioiodinated Small Molecule Tyrosine Kinase Inhibitor for HER2 Selective SPECT Imaging. |
Q36271681 | Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer |
Q48018514 | Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy |
Q91130415 | Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16) |
Q88385844 | Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results |
Q55068762 | Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer. |
Q55302749 | Rapid micro fluorescence in situ hybridization in tissue sections. |
Q55346946 | Rapid progression of a granulocyte colony-stimulating factor-producing liver tumor metastasized from esophagogastric junction cancer: A case report and literature review. |
Q64284818 | Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant |
Q36085254 | Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients |
Q31023009 | Real-world data in the molecular era-finding the reality in the real world |
Q93106855 | Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients |
Q54269156 | Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. |
Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
Q92713306 | Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer |
Q28083123 | Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates |
Q64078518 | Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer |
Q97070217 | Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution |
Q30814798 | Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. |
Q55003632 | Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. |
Q35710389 | Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer |
Q53227861 | Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection. |
Q38618238 | Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks |
Q54198492 | Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. |
Q92836078 | Relationship Study of The Verified H uman Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization |
Q58801931 | Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment |
Q92413714 | Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer |
Q92270942 | Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas |
Q51396553 | Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. |
Q54207067 | Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study. |
Q48719284 | Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume |
Q88391702 | Reply to Commentary on 'HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features' |
Q36168078 | Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer |
Q35525379 | Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule |
Q33632008 | Reproductive risk factors and breast cancer subtypes: a review of the literature |
Q38420000 | Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size |
Q36260485 | Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. |
Q35539538 | Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study |
Q42360663 | Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.). |
Q40614123 | Resting heart rate as a prognostic factor for mortality in patients with breast cancer |
Q91760466 | Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer |
Q47410999 | Retrospective analysis of the association between human epidermal growth factor receptor 2 amplification and chromosome enumeration probe 17 status in patients with breast cancer |
Q33433275 | Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. |
Q38662712 | Review: circulating tumor cells in the practice of breast cancer oncology. |
Q50271137 | Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. |
Q39150776 | Rifaximin for Pertuzumab-Related GI Toxicities |
Q35949292 | Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers |
Q58694213 | Risk factors for the development of brain metastases in patients with HER2-positive breast cancer |
Q93271903 | Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis |
Q40490703 | Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis |
Q61623284 | Robust identification of target genes and outliers in triple-negative breast cancer data |
Q33858981 | Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China. |
Q63247308 | Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer |
Q34004215 | Role of the neural niche in brain metastatic cancer |
Q59804254 | RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples |
Q38882282 | S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. |
Q38420953 | SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. |
Q33643210 | SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer |
Q92814902 | Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 |
Q37498654 | Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results |
Q60913102 | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial |
Q47644645 | Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study |
Q53121949 | Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast. |
Q88766337 | Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute |
Q38199005 | Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin? |
Q90094958 | Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma |
Q91629028 | Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women |
Q91709234 | Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease |
Q41698982 | Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case-control study. |
Q37109466 | Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status |
Q38914932 | Short formalin fixation and rapid microwave processing do not affect HER2 testing |
Q92812431 | Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience |
Q36847236 | Significance of Matrix Metalloproteinase 9 Expression as Supporting Marker to Cytokeratin 19 mRNA in Sentinel Lymph Nodes in Breast Cancer Patients |
Q40214905 | Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy |
Q61796812 | Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine |
Q58567273 | Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy |
Q35174533 | Significance of rat mammary tumors for human risk assessment |
Q57477210 | Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2 |
Q47392563 | Single-cell heterogeneity in ductal carcinoma in situ of breast. |
Q91176710 | Single-cell protein profiling in microchambers with barcoded beads |
Q47561778 | Solid papillary carcinoma of the breast with an associated Cytokeratin 7- negative Paget's disease of the nipple. Report of a first case. |
Q55280468 | Somatic mutations in early onset luminal breast cancer. |
Q33914716 | Somatic mutations in leukocytes infiltrating primary breast cancers |
Q47133482 | Somatic mutations in salivary duct carcinoma and potential therapeutic targets. |
Q48088751 | Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. |
Q38747685 | Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound |
Q34283751 | Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study |
Q50941816 | Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. |
Q40409180 | St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. |
Q49494949 | Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience |
Q41469992 | Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients |
Q37721631 | Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients |
Q36640187 | Stromal expression of matrix metalloproteinase 2 in cancer-associated fibroblasts is strongly related to human epidermal growth factor receptor 2 status in invasive breast carcinoma |
Q90711534 | Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
Q38268585 | Subtyping of breast cancer using reverse phase protein arrays |
Q35826503 | Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
Q58567692 | Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status |
Q37359309 | Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience |
Q36863215 | Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer |
Q38209628 | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline |
Q38209464 | Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives. |
Q39685521 | T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab |
Q91872237 | T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer |
Q92298870 | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases |
Q40810058 | TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. |
Q36376097 | TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays |
Q41660785 | TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling |
Q37697225 | TTK is a favorable prognostic biomarker for triple-negative breast cancer survival |
Q37694797 | Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study |
Q39147161 | Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer |
Q39238692 | Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance |
Q90862850 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer |
Q26768119 | Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives |
Q99408604 | Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications |
Q55071512 | Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. |
Q34309927 | Targeting MET Amplification as a New Oncogenic Driver. |
Q38741697 | Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? |
Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
Q35687706 | The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas |
Q89428605 | The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment |
Q36087106 | The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis |
Q26738677 | The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics |
Q55026325 | The FlexISH assay brings flexibility to cytogenetic HER2 testing. |
Q41739963 | The Genomic Landscape of Male Breast Cancers |
Q64882616 | The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. |
Q58601441 | The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers |
Q34654520 | The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. |
Q38700451 | The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control |
Q40777892 | The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition |
Q52733226 | The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. |
Q48065393 | The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic |
Q99591067 | The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer |
Q36653693 | The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. |
Q35874075 | The Values of Combined and Sub-Stratified Imaging Scores with Ultrasonography and Mammography in Breast Cancer Subtypes |
Q47372771 | The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes |
Q38802932 | The assessment of HER2 status in breast cancer: the past, the present, and the future |
Q85798864 | The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer |
Q37697200 | The associations between mast cell infiltration, clinical features and molecular types of invasive breast cancer |
Q41616706 | The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers |
Q52647074 | The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation. |
Q91834210 | The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution |
Q47372732 | The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016. |
Q33739274 | The clinical significance of accompanying NME on preoperative MR imaging in breast cancer patients |
Q89902062 | The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma |
Q37716582 | The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer |
Q90259059 | The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status |
Q38827388 | The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients |
Q92714905 | The discordance pattern of molecular sub-types between primary and metastatic sites in Chinese breast cancer patients |
Q36139739 | The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study |
Q53842791 | The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. |
Q55058089 | The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study. |
Q92604752 | The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer |
Q38192017 | The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy |
Q49978231 | The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions |
Q26775232 | The fate of chemoresistance in triple negative breast cancer (TNBC) |
Q36266449 | The frequency and clinical impact of HER2 alterations in lung adenocarcinoma |
Q49270812 | The genetic landscape of breast carcinomas with neuroendocrine differentiation |
Q100752677 | The genomic landscape of metastatic histologic special types of invasive breast cancer |
Q33692695 | The human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ [...] |
Q94521566 | The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization |
Q41382068 | The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients. |
Q38591049 | The importance of surgical margins in breast cancer |
Q37425427 | The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case |
Q36681892 | The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index |
Q64065309 | The landscape of d16HER2 splice variant expression across HER2-positive cancers |
Q92785578 | The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy |
Q86628860 | The pre-analytical phase in surgical pathology |
Q92643282 | The prognostic and predictive potential of Ki-67 in triple-negative breast cancer |
Q37376414 | The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy |
Q46842412 | The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer |
Q52627272 | The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. |
Q33607142 | The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment. |
Q36110190 | The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. |
Q37232177 | The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study |
Q42380390 | The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform |
Q48301715 | The role of skin ulceration in breast carcinoma staging and outcome. |
Q90484944 | The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype |
Q38175061 | The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice |
Q55033826 | The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. |
Q34268618 | Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer |
Q47638243 | Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. |
Q37628969 | Therapeutic implication of HER2 in advanced biliary tract cancer |
Q61814603 | Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry |
Q89791409 | Three-dimensional radiomics of triple-negative breast cancer: Prediction of systemic recurrence |
Q90317011 | Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer |
Q55424081 | Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases. |
Q91974174 | Towards personalized treatment for early stage HER2-positive breast cancer |
Q37350784 | Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases |
Q27853001 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial |
Q92886181 | Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature |
Q28077666 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives |
Q34538368 | Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study |
Q35740877 | Treatment of HER2-positive breast cancer. |
Q91045690 | Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016) |
Q90476366 | Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies |
Q91989188 | Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease |
Q55397856 | Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. |
Q90394997 | Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile |
Q36640582 | Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα. |
Q33769821 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease |
Q33915057 | Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants |
Q36000688 | Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. |
Q47146956 | Tumor Heterogeneity in Breast Cancer |
Q28554412 | Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes |
Q49987138 | Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy |
Q47573583 | Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer. |
Q37564576 | Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer |
Q64284503 | Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer |
Q48219547 | Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer. |
Q49494144 | Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer |
Q42315538 | TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy |
Q47863345 | Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer |
Q36658298 | Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity |
Q92726377 | Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene |
Q91152086 | Two types of primary mucinous ovarian tumors can be distinguished based on their origin |
Q54293691 | Two-temperature formalin fixation preserves activation states efficiently. |
Q50038885 | Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy for Guidance of Axillary Surgery in Breast Cancer Patients: Experience with Activated Charcoal. |
Q93018293 | Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study |
Q36319218 | Unexpected Symptomatic Pneumonitis Following Breast Tangent Radiation: A Case Report |
Q35496577 | Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. |
Q58803565 | Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer |
Q38932758 | Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer |
Q52587869 | Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. |
Q35048548 | Updated UK Recommendations for HER2 assessment in breast cancer |
Q28079118 | Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline |
Q33817285 | Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline |
Q38526035 | Use of Immunohistochemical Stains in Epithelial Lesions of the Breast |
Q38723467 | Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients. |
Q36743446 | Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma. |
Q45057063 | Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial |
Q89986543 | Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer |
Q87494494 | Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens |
Q60921036 | Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas |
Q46082799 | Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer |
Q57192072 | Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China |
Q91692152 | Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer |
Q28075719 | Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation |
Q98302968 | Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution |
Q39022194 | Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients. |
Q89665021 | Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas |
Q37595980 | Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models |
Q37407384 | Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases |
Q44521334 | Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility |
Q48301412 | Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET. |
Q85281790 | We are all individuals... bioinformatics in the personalized medicine era |
Q39053758 | Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing? |
Q92624799 | Whole-exome and whole-transcriptome sequencing of canine mammary gland tumors |
Q41708245 | Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples |
Q47150037 | Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation |
Q39794283 | [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer |
Q85484175 | [Genomic signature of breast cancer: The quest for the Holy Grail] |
Q53073585 | [HER2 testing in gastric cancer : Results of a meeting of German experts]. |
Q57110598 | [Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies] |
Q52868166 | [Molecular pathology for breast cancer: Importance of the gene expression profile]. |
Q35795297 | c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer |
Q40858674 | c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer |
Q37707589 | mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer |
Q89842473 | miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil |
Q43595352 | p-mTOR expression is associated with better prognosis in luminal breast carcinoma |
Q34786457 | p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. |
Search more.